Your browser doesn't support javascript.
loading
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Venet, Melany; Lepine, Anne; Maarouf, Adil; Biotti, Damien; Boutiere, Clémence; Casez, Olivier; Cohen, Mikael; Durozard, Pierre; Demortière, Sarah; Giorgi, Laetitia; Maillart, Elisabeth; Mathey, Guillaume; Mazzola, Laure; Rico, Audrey; Camdessanche, Jean-Philippe; Deiva, Kumaran; Pelletier, Jean; Audoin, Bertrand.
Affiliation
  • Venet M; Department of Neurology, Aix Marseille Univ, APHM, Hôpital de la Timone, CNRS, CRMBM, Marseille, France.
  • Lepine A; Neurology Department, University Hospital, Saint-Etienne, France.
  • Maarouf A; Paediatric Neurology Department, Assistance Publique des Hôpitaux de Marseille, Hôpital Universitaire, Marseille, France.
  • Biotti D; Department of Neurology, Aix Marseille Univ, APHM, Hôpital de la Timone, CNRS, CRMBM, Marseille, France.
  • Boutiere C; Centre Ressources et Compétences Sclérose en Plaques (CRC-SEP) et Service de Neurologie B4, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Toulouse, France.
  • Casez O; INSERM UMR1291-CNRS UMR5051, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse 3, Toulouse, France.
  • Cohen M; Department of Neurology, Aix Marseille Univ, APHM, Hôpital de la Timone, CNRS, CRMBM, Marseille, France.
  • Durozard P; Neuro-inflammatory Disease Center, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.
  • Demortière S; CRC-SEP CHU Nice, UR2CA-URRIS, Université Nice Cote d'Azur, Hôpital Pasteur 2, Nice, France.
  • Giorgi L; Centre Hospitalier d'Ajaccio, Ajaccio, France.
  • Maillart E; Department of Neurology, Aix Marseille Univ, APHM, Hôpital de la Timone, CNRS, CRMBM, Marseille, France.
  • Mathey G; Department of Paediatric Neurology, National Reference Center for Rare Inflammatory and auto-immune Brain and Spinal Diseases, Hopitaux Universitaires Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicetre, France.
  • Mazzola L; UMR 1184, Immunology of Viral Infections and Autoimmune Diseases, Universite Paris Saclay, Le Kremlin-Bicetre, France.
  • Rico A; Department of Neurology, National Reference Center for Rare Inflammatory and auto-immune Brain and Spinal Diseases, Pitie Salpetriere Hospital, APHP, Paris, France.
  • Camdessanche JP; Neurology Unit, University Hospital of Nancy, Hôpital Central, Nancy Cedex, France.
  • Deiva K; Neurology Department, University Hospital, Saint-Etienne, France.
  • Pelletier J; Department of Neurology, Aix Marseille Univ, APHM, Hôpital de la Timone, CNRS, CRMBM, Marseille, France.
  • Audoin B; Neurology Department, University Hospital, Saint-Etienne, France.
Mult Scler ; 30(2): 261-265, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38166437
ABSTRACT
Recent studies in adults suggested that extended-interval dosing of rituximab/ocrelizumab (RTX/OCR) larger than 12 months was safe and could improve safety. This was an observational cohort study of very active pediatric-onset multiple sclerosis (PoMS) (median (range) age, 16 (12-17) years) treated with RTX/OCR with 6 month standard-interval dosing (n = 9) or early extended-interval dosing (n = 12, median (range) interval 18 months (12-25)). Within a median (range) follow-up of 31 (12-63) months after RTX/OCR onset, one patient (standard-interval) experienced relapse and no patient showed disability worsening or new T2-weighted lesions. This study suggests that the effectiveness of RTX/OCR is maintained with a median extended-interval dosing of 18 months in patients with very active PoMS.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: France